Novartis is a multinational biopharmaceutical company. According to its disclosures, it lobbies on health-related issues such as policies for cell and gene therapies and radioligand therapies, pharmaceutical pricing, development of treatments for rare diseases, the 340B drug discount program, and supply chain matters. It reports hiring Brownstein Hyatt Farber Schreck and spent about $300,000 across four filings.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
ADAM STEINMETZ
The latest disclosures for this client.
BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q4BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q3The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
BROWNSTEIN HYATT FARBER SCHRECK, LLP
ANDREW USYK
BROWNSTEIN HYATT FARBER SCHRECK, LLP
DEEMA TARAZI
BROWNSTEIN HYATT FARBER SCHRECK, LLP
EMILY FELDER
BROWNSTEIN HYATT FARBER SCHRECK, LLP
ZACHARY PFISTER
BROWNSTEIN HYATT FARBER SCHRECK, LLP
GREGORY SUNSTRUM
BROWNSTEIN HYATT FARBER SCHRECK, LLP
DAVID REID
BROWNSTEIN HYATT FARBER SCHRECK, LLP
NADEAM ELSHAMI
BROWNSTEIN HYATT FARBER SCHRECK, LLP
BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q2BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q1